How did GoodRx's revenue and expenses trend in Q4 2024?

GoodRx's revenue and expenses in Q4 2024 are not currently available. However, we can infer trends based on available financial data from Q3 2024.

1. Revenue Trend: GoodRx reported an 8% year-over-year increase in total revenue for Q3 2024, reaching $195.3 million. This growth was primarily driven by an 8% increase in prescription transactions revenue, which amounted to $140.4 million. In contrast, subscription revenue decreased by 8% to $21.3 million. The Pharma Manufacturer Solutions segment experienced a significant surge, with a 77% year-over-year growth, generating $28.1 million.
2. Expense Trends: GoodRx's net income for Q3 2024 was $4.0 million, compared to a net loss of $38.5 million in the same period the previous year. Adjusted net income was $31.9 million, reflecting a substantial improvement from $25.5 million in Q3 2023. The company's adjusted EBITDA increased by 21.5% year-over-year, reaching $65.0 million, and adjusted EBITDA margin improved by 520 basis points to 33.3%.
3. Cash Flow: GoodRx reported a strong cash flow performance, with net cash provided by operating activities amounting to $86.9 million, up from $60.3 million in the same period the previous year.

In conclusion, GoodRx demonstrated robust revenue growth and significant improvements in profitability in Q3 2024, despite challenges in the retail pharmacy environment. While specific Q4 2024 data is not available, the trends observed in Q3 suggest that GoodRx was likely to continue its trajectory of growth and financial improvement.